Børsmeldinger | Aqua Bio Technology ASA

AQUA BIO TECHNOLOGY ASA - RESULT OF SUBSEQUENT OFFERING – UPDATE OF PROPOSAL FOR THE EXTRAORDINARY GENERAL MEETING4.4.2025 08:00:00 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "Company") on 27 March 2025 regarding a subsequent offering with gross proceeds of up to NOK 10,000,000 through issuance of up to 20,000,000 new shares at a subscription price of NOK 0.50 per share (the "Subsequent Offering"). In the Subsequent Offering, the shareholders of the Company as of 11 March 2025 (as registered in the VPS on 13 March 2025), except: (i) shareholders that subscribed for shares in the private placement placed on 11 March 2025, and (ii) shareholders who are resident in a jurisdiction where such offering would be unlawful, or would require any prospectus filing, registration or similar action (the "Eligible Shareholders"), received subscription rights giving preferential rights to subscribe for and be allocated new shares in the Subsequent Offering (the "Offer Shares"). In addition, certain groups of investors, as described in the stock exchange notice dated 27 March 2025 were given a se

2 vedlegg

Aqua Bio Technology ASA: Last day of Subscription Period in Subsequent Offering3.4.2025 12:34:09 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN Reference is made to the stock exchange announcements by Aqua Bio Technology ASA ("ABTEC" or the "Company") on 26 March 2025 regarding the terms of a subsequent offering of up to 20,000,000 new shares (the "Offer Shares") in the Company (the "Subsequent Offering") and on 27 March 2025 regarding the start of the subscription period in the Subsequent Offering. Each Offer Share is offered at a subscription price of NOK 0.50. The subscription period for the Subsequent Offering (the "Subscription Period") will expire today, 3 April 2025 at 16:30 hours (CEST). Subscription rights that are not used to subscribe for Offer Shares before the expiry of th

1 vedlegg

Aqua Bio Technology ASA: Subsequent Offering – Start of Subscription Period27.3.2025 08:00:00 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN Reference is made to the stock exchange announcement by Aqua Bio Technology ASA ("ABT" or the "Company") on 26 March 2025 regarding the terms of a subsequent offering of new shares in the Company (the "Subsequent Offering"). The Subsequent Offering consists of an offering of up to 20,000,000 new shares in the Company (the "Offer Shares") directed towards the shareholders of the Company as of 11 March 2025 (as registered in the VPS on 13 March 2025) (the "Record Date"), except; (i) shareholders that subscribed for shares in the Private Placement, and (ii) shareholders who are resident in a jurisdiction where such offering would be unlawful, or w

2 vedlegg

Aqua Bio Technology ASA: Terms of the Subsequent Offering26.3.2025 08:00:06 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN Reference is made to the stock exchange announcements by Aqua Bio Technology ASA ("ABTEC" or the "Company") on 11 March 2025 regarding the completion of a private placement that raised approximately NOK 24.2 million in gross proceeds, to be settled through both conversion of previously incurred debt and through advance cash payments (the "Private Placement") and a subsequent offering of new shares in the Company (the "Subsequent Offering"). The Subsequent Offering consists of an offering of up to 20,000,000 new shares in the Company (the "Offer Shares") directed towards the shareholders of the Company as of 11 March 2025 (as registered in the V

1 vedlegg

Aqua Bio Technology: Notice of extraordinary general meeting19.3.2025 11:41:42 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

An extraordinary general meeting of Aqua Bio Technology ASA (the "Company" or "ABTEC") will be held on 9 April 2025 at 10:00 (CET) at Advokatfirmaet CLP DA, Sommerrogata 13-15, 0255 Oslo. Please find attached the notice to the general meeting. All documents to be treated at the general meeting will be made available at the Company's website www.aquabiotechnology.com - http://www.aquabiotechnology.com. Shareholders who wish to the attend the general meeting is requested to notify the Company as set out in Appendix 1 to the notice within 7 April 2025 at 16:00 (CET). In case of attendance by proxy, the proxy form (also included in appendix 1 to the notice) is requested submitted to be received by the Company within the same date. For further information, please contact Fredrik Henriksen, CEO Phone +47 900 20 078 Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective, and they prov

2 vedlegg

Aqua Bio Technology ASA – Ex. date for Subsequent Offering today12.3.2025 08:49:28 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the announcement by Aqua Bio Technology ASA on 11 March 2025 concerning the successful placement of the conditional private placement with total gross proceeds of approximately NOK 24.2 million, and a contemplated subsequent offering (the "Subsequent Offering"), and to the announcement with key information for the Subsequent Offering. The shares in Aqua Bio Technology ASA will be traded exclusive of the right to receive subscription rights in the Subsequent Offering as of today, 12 March 2025. This information is published in accordance with the requirements of the Continuing Obligations in Euronext Rule Book II.

1 vedlegg

Aqua Bio Technology ASA – Key information relating to the Subsequent Offering11.3.2025 23:47:17 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the announcement by Aqua Bio Technology ASA on 11 March 2025 concerning the successful placement of the conditional private placement with total gross proceeds of approximately NOK 24.2 million, and a contemplated subsequent offering (the "Subsequent Offering"). Key information for the Subsequent Offering is set out below: Date on which the terms of the Subsequent 11 March 2025 Offering was announced: Last day including right: 11 March 2025 First day excluding right: 12 March 2025 Record date: 13 March 2025 EGM date: On or about 8 April 2025 (to be summoned) Maximum number of new shares: 20,000,000 Subscription price: NOK 0.50 Shall the rights be listed No The issuance of new shares in the Subsequent Offering will be subject to approval of the pertaining share capital increase by the EGM to be held on or about 4 April 2025. The Board will assess the appropriate size of the Subsequent Offering and announce the final number of Offer Shares to be offered shortly prior

1 vedlegg

Aqua Bio Technology ASA – Private Placement successfully placed11.3.2025 23:43:57 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from Aqua Bio Technology ASA ("ABT" or the "Company") published on 7 March 2025 regarding a contemplated conditional private placement of minimum 26,000,000 and maximum 60,000,000 new shares in the Company (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 0.50 per New Share (the "Private Placement"), as well as to the stock exchange notices dated 10 March 2025 and 11 March 2025 regarding extension of the application periods in the Private Placement. The Company is pleased to announce that it has now rais

1 vedlegg

Correction: Aqua Bio Technology ASA: Private Placement – Further extension of Application Period11.3.2025 09:15:36 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcements from Aqua Bio Technology ASA ("ABTEC" or the "Company", and together with its consolidated subsidiaries, the "Group") on 7 March 2025 regarding the launch of a conditional private placement (the "Private Placement") of new shares (the "New Shares") in the Company, and to the stock exchange notice dated 10 March 2025 regarding an extension of the application period in the Private Placement. The Company's Board of Directors have now resolved to extend the application period in the Private Placement further, until 12 March 2025 at 08.00 CET. The Board of Directors reserves the right to shorten or

1 vedlegg

Aqua Bio Technology ASA: Private Placement – Further extension of Application Period11.3.2025 08:56:22 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcements from Aqua Bio Technology ASA ("ABTEC" or the "Company", and together with its consolidated subsidiaries, the "Group") on 7 March 2025 regarding the launch of a conditional private placement (the "Private Placement") of new shares (the "New Shares") in the Company, and to the stock exchange notice dated 10 March 2025 regarding an extension of the application period in the Private Placement. The Company's Board of Directors have now resolved to extend the application period in the Private Placement further, until 121 March 2025 at 08.00 CET. The Board of Directors reserves the right to shorten or

1 vedlegg

Aqua Bio Technology ASA: Private Placement – Extension of Application Period10.3.2025 08:55:07 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcements from Aqua Bio Technology ASA ("ABTEC" or the "Company", and together with its consolidated subsidiaries, the "Group") on 7 March 2025 regarding the launch of a conditional private placement (the "Private Placement") of new shares (the "New Shares") in the Company. The Company's Board of Directors have now resolved to extend the application period in the Private Placement until 11 March 2025 at 08.00 CET. The Board of Directors reserves the right to shorten or extend the application period in the Private Placement at any time and for any reason. Subject to the application period being closed on

1 vedlegg

Aqua Bio Technology ASA – Contemplated Private Placement – Financial and operational update7.3.2025 18:17:20 CET | Aqua Bio Technology ASA | Inside information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Aqua Bio Technology ASA ("ABT" or the "Company", and together with its consolidated subsidiaries, the "Group") hereby announces a contemplated conditional private placement of minimum 26 million and maximum 60 million new shares (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 0.50 per New Share (the "Private Placement"). The Company further contemplates to carry out a subsequent offering towards eligible shareholders. The Private Placement is carried out in order to improve the Company's financial position. An update on the Company's financial posi

1 vedlegg

Specification regarding expected results for 202414.2.2025 13:57:58 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA ('ABT' or 'the Company') announced on February 12, 2025, that the negative result for 2024 is primarily due to significant impairments of goodwill related to the bankruptcy of its subsidiary, Skinteam Norge AS, as well as operating losses in two of the Group's subsidiaries. ABT emphasizes that the majority of the operating losses in two subsidiaries in 2024 are due to significant and extraordinary impairments. - The impairments position the group better to deliver shareholder value in the future,' says Fredrik William Henriksen.

1 vedlegg

Spesifisering vedrørende forventede resultater for 202414.2.2025 13:57:33 CET | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology ASA ("ABT" eller "Selskapet") informerte den 12.2 2025 om at negativt resultat for 2024 i all hovedsak skyldes betydelige nedskrivninger av goodwill i forbindelse med konkursen i datterselskapet Skinteam Norge AS, samt driftsunderskudd i to av konsernets datterselskaper. ABT vil påpeke at majoriteten av driftsunderskuddene i to datterselskap i 2024 skyldes at det er foretatt betydelige og ekstraordinære nedskrivninger. - Nedskrivningene gjør at konsernet er bedre posisjonert til å kunne levere aksjonærverdier i fremtiden, sier Fredrik William Henriksen.

1 vedlegg

Aqua Bio Technology ASA: Information about financial reporting and expected results for 202412.2.2025 14:40:08 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA ("ABT" or "the Company") hereby informs that a separate quarterly report for the fourth quarter of 2024 will not be prepared. The annual financial statements for 2024 will be submitted no later than the deadline of April 30, 2025. A stock exchange announcement with the financial calendar will be sent separately. Preliminary estimates for the fiscal year 2024 indicate a significant negative result for the ABT Group, despite an increase in revenue due to completed acquisitions. The negative result is mainly attributed to operating losses in two of the Group's subsidiaries and significant impairments of goodwill related to the bankruptcy of the subsidiary Skinteam Norge AS. In light of this, the Group plans a series of restructuring measures expected to contribute to a modestly positive EBITDA level for 2025. For the fiscal year 2025, consolidated revenue is expected to exceed MNOK 500.0, applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicat

1 vedlegg

Aqua Bio Technology ASA: Informasjon om finansiell rapportering og forventede resultater for 202412.2.2025 14:39:16 CET | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology ASA ("ABT" eller "Selskapet") informerer herved om at det ikke vil utarbeides en separat kvartalsrapport for fjerde kvartal 2024. Årsoppgjøret for 2024 vil bli avlagt senest ved fristens utløp 30. april 2025. Børsmelding med finansiell kalender vil sendes separat. Foreløpige estimater for regnskapsåret 2024 indikerer et betydelig negativt resultat for ABT-konsernet, men også en økning i omsetning på grunn av gjennomførte oppkjøp. Det negative resultatet skyldes hovedsakelig driftsunderskudd i to av konsernets datterselskaper, samt betydelige nedskrivninger av goodwill i forbindelse med konkursen i datterselskapet Skinteam Norge AS. I lys av dette planlegger konsernet en rekke omstruktureringstiltak som forventes å bidra til et svakt positivt EBITDA-nivå for 2025. For regnskapsåret 2025 forventes det en samlet omsetning på over MNOK 500,0 når man legger til grunn Norsk God Regnskapsskikk (N-GAAP), som indikerer en konservativ omsetningsvekst sammenlignet med pro-form

1 vedlegg

Aqua Bio Technology: Board member resignation21.1.2025 10:07:28 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA (the "Company" or "ABT") has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment. For further information, please contact CEO Fredrik William Henriksen phone +47 90 02 00 78. About Aqua Bio Technology ASA ASA Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand. This information is subject to the disclosure requirements in sections 4-2 and 5-12 of the Norwegian Securitie

1 vedlegg

Geir Udnæs new CFO in Aqua Bio Technology6.1.2025 08:45:01 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology has appointed Geir Udnæs as interim CFO. Udnæs is an auditor with a broad and comprehensive career. - We are proud to have a capacity like Geir on the team. For ABT, this is an important part of the ongoing professionalization of the company. As the company has moved from little activity to now being able to show significant growth, it is essential that the team is also strengthened in key positions. An added bonus is that Geir also knows the industry from before, says CEO Fredrik William Henriksen. Udnæs has previously, among other things, been an auditor at Arthur Andersen, CFO at Kistefos, CEO at Midelfart and has extensive experience from corporate services and transactions. - ABT is a very exciting company in an interesting market. I look forward to working with Fredrik and the others in ABT in the future, says Udnæs. For further information, please contact CEO Fredrik William Henriksen phone +47 90 02 00 78. Aqua Bio Technology (ABT) is developing and commerci

1 vedlegg

Geir Udnæs ny CFO i Aqua Bio Technology6.1.2025 08:45:00 CET | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology har utnevnt Geir Udnæs som interim CFO. Udnæs er utdannet revisor med en bred og omfattende karriere. - Vi er stolte av å få med en kapasitet som Geir på laget. For ABT er dette en viktig del i den pågående profesjonaliseringen av selskapet. I takt med at selskapet har beveget seg fra lite aktivitet, til å nå kunne vise betydelig vekst, er det essensielt at laget også styrkes i sentrale posisjoner. En ekstra bonus er at Geir også kjenner til bransjen fra tidligere, sier CEO Fredrik William Henriksen. Udnæs har tidligere blant annet vært revisor i Arthur Andersen, CFO i Kistefos, CEO i Midelfart og med lang erfaring fra finansiell rådgivning og transaksjoner. - ABT er et veldig spennende selskap i et interessant marked. Jeg ser frem til å jobbe med Fredrik og de andre i ABT i tiden som kommer, sier Udnæs. For ytterligere informasjon, vennligst kontakt Fredrik William Henriksen, CEO, telefon +47 90 02 00 78. Aqua Bio Technology (ABT) utvikler og kommersialiserer bærek

1 vedlegg

Aqua Bio Technology ASA – Signed LOI for sale for at least 250 million18.12.2024 09:56:06 CET | Aqua Bio Technology ASA | Inside information

Exclusive agreement linked to the largest retailers in Germany, Austria, Switzerland and the UAE. 3D Innovation Nordic AS ("3D"), a wholly owned subsidiary of Aqua Bio Technology, has entered into an LOI for the sale of Non-food for at least NOK 250 million over 5 years, which is the largest agreement the company has ever entered into. The agreement has been concluded with a major German wholesaler, who will receive 5 years of exclusivity linked to several of 3D's products for the markets in Germany, Austria, Switzerland and the UAE. The agreement that has now been concluded is aimed at the largest retailers in Germany, which means that the potential is significantly greater. - This is a significant and potentially historically large agreement for Aqua Bio Technology. It shows that the strategy of targeted and good acquisitions for distribution is bearing fruit. Furthermore, the potential in the agreement is significantly greater than this. After all, we are talking about an agreement

1 vedlegg